CVRX — CVRx, Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1235912 ·
Last close
$3.15
Market Cap
$83.92M
52W High
$6.23
52W Low
$2.20
ADV30
1,146,250
Next earnings
2026-11-05
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 15,705,000 13,724,000 -13,023,000 -14,044,000 92,283,000 64,586,000 72,330,000
Mar 2026 14,769,000 12,881,000 -12,161,000 -13,120,000 99,728,000 72,303,000 70,619,000
Dec 2025 16,024,000 13,825,000 -11,184,000 -11,934,000 104,794,000 75,708,000 65,470,000
Sep 2025 14,690,000 12,753,000 -12,268,000 -12,870,000 111,325,000 85,124,000 63,271,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-40,457,000
Investing CF
$-597,000
Financing CF
$10,616,000
CapEx
$-597,000
Dividends Paid
Buybacks
$-43,000
EPS Diluted TTM
$-1.98
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-617,816,000
Inventory
$13,028,000
Receivables
$9,401,000
ST Investments
EBIT TTM
$-45,948,000
Pretax Income TTM
$-51,974,000
Interest Exp TTM
$6,026,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$61,188,000
EBITDA
$-47,843,000
Free Cash Flow
$-23,801,750
Enterprise Value
$78,725,032
Total Cash
$64,586,000
Total Debt
$59,390,000
Shares Out
26,641,597
Trailing EPS
$-1.97
Book Value
$0.75
ROE
-133.4%
ROA
-28.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 56,651,000 -51,265,000 -53,306,000 104,794,000 65,470,000 -40,170,000
Dec 2024 51,292,000 -59,490,000 -59,965,000 133,414,000 62,359,000 -39,144,000
Dec 2023 39,295,000 -43,103,000 -41,199,000 115,229,000 39,282,000 -39,021,000
Dec 2022 22,469,000 -42,527,000 -41,428,000 124,937,000 15,757,000 -42,677,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.88

Max Pain — expiry 2026-09-18

max pain strike: $2.50 · spot: $3.20 · call oi: 428 · put oi: 752
Expected Move to 2026-09-18: ±$0.73 (22.66%) — implied range $2.48$3.93 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ECOR electroCore, Inc. $87.00M $9.65
SKIN SkinHealth Systems Inc. $88.50M $0.68
STEX Streamex Corp. $89.08M $0.76
OM Outset Medical, Inc. $78.76M $4.19
HYPR Hyperfine, Inc. $77.92M $0.86

News headlines (Yahoo Finance, 1h cache)

CVRx Responds to Letter from Pointillist Family Office
2026-08-25 12:00 · Yahoo
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
2026-08-24 12:30 · Yahoo
CVRx (CVRX) Q2 2026 Earnings Call Transcript
2026-08-13 22:15 · Yahoo
CVRx Announces Sales Leadership Transition
2026-08-11 11:00 · Yahoo
CVRx Inc (CVRX) (Q2 2026) Earnings Call Highlights: Sales Execution Challenges Offset Strong ...
2026-08-07 05:08 · Yahoo
CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates
2026-08-07 02:35 · Yahoo
CVRx Q2 Earnings Call Highlights
2026-08-07 01:03 · Yahoo
Compared to Estimates, CVRx (CVRX) Q2 Earnings: A Look at Key Metrics
2026-08-07 00:00 · Yahoo
CVRx Reports Second Quarter 2026 Financial and Operating Results
2026-08-06 20:05 · Yahoo
CVRx (CVRX) Moves 11.6% Higher: Will This Strength Last?
2026-06-29 10:44 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.